Uncoupling Relapse Reduction and Disability Progression
The aim of this study was to evaluate whether the treatment effects of tolebrutinib on confirmed disability worsening (CDW) diverge from its effects on relapse prevention compared with other disease-modifying therapies (DMTs) for relapsing multiple sclerosis (MS).
Authors
- Alessio Signori (ORCID: https://orcid.org/0000-0001-6289-9144)
- Noemi Montobbio (ORCID: https://orcid.org/0000-0003-0302-393X)
- Irene Schiavetti
- Alessandra Krenn
- Francesca Bovis
- Maria Pia Sormani
- Marta Ponzano
Institutions
- Ospedale Policlinico San Martino (IT)
- University of Genoa (IT)
Publication Details
- Journal
- Neurology Clinical Practice
- Published
- 2026-04-06
- DOI
- https://doi.org/10.1212/cpj.0000000000200612
- Primary Topic
- Lower Extremity Biomechanics and Pathologies
- Type
- article
- Field-Weighted Citation Impact
- 0.00